The Saul and Joyce Brandman Breast Center - A Project of Women's Guild is dedicated to bringing new diagnosis and treatment options and technology to our patients through clinical trials and research. Clinical trials lead the way to better treatments and improved survival for breast cancer patients.
The following is a list of currently open clinical trials and research studies.
Cedars-Sinai Breast Center Patient Registry
The purpose of this study is to establish a comprehensive registry of patients treated at the Breast Center for use in future prospective and retrospective breast cancer risk factor analyses in order to: 1) develop a better model to predict breast cancer risk in individual patients; 2) develop novel and cost-effective methods to screen for breast cancer risk; 3) identify patients who are candidates for participation in interventional clinical trials; and 4) track the outcomes of patients who are treated at the Breast Center so that opportunities to improve care may be identified.
(IRB# 21434) PI: Catherine Dang, MD
- Women and Men
- 18 years or age or older
Blood, Tissue, Saliva, and Clinical Data Collection for Breast Cancer Research
The investigators listed above are collecting blood, tissue, and other body fluids including saliva, and clinical information. The purpose of this study is to identify genes and/or other proteins/molecules that influence a person's risk of getting cancer of the breast, to discover new tests and treatments for breast cancer, to further our understanding of breast cancer and learn whether we can predict how individuals with a particular cancer of the breast will respond to treatments.
(IRB# 3870) PI: Beth Karlan, MD
- You are scheduled to have a surgical procedure that may involve the removal of some or all of your breast tissue
- You are a man or woman with a family history of breast cancer
- You are a patient being seen in the Saul and Joyce Brandman Breast Center for breast health evaluation or care
Gilda Radner Hereditary Cancer Detection Study
This research is being done to evaluate standard and new screening methods, which may detect ovarian, peritoneal or breast cancer at an early stage in women who are at high risk because they have known BRCA1 or BRCA2 genetic alterations, which predispose for these diseases.
(IRB# 1080) PI: Beth Karlan, MD
- A known BRCA1 or BRCA2 mutation
Molecular Breast Imaging--Implications for Early Detection of Breast Cancer and Optimizing Cancer Diagnosis and Treatment
This research study is designed to compare a new imaging test, the Lumagem® dual headed small field gamma camera, with conventional breast imaging (mammography, ultrasound and MRI) to see which is most effective in detecting small breast tumors.
(IRB# 17011) PI: Alan Waxman, MD
- 18 years of age or older
- With a suspicious abnormality on conventional breast imaging (mammogram or ultrasound)
a. Unilateral or Bilateral
b. Less than 2cm in size
c. Imaging rated BIRADS category 4 or 5 for whom a biopsy has been recommended
- Not pregnant
a. Negative pregnancy test in patients of child bearing capability
b. Post menopausal women
c. Women who have had prior hysterectomy
- Currently lactating
- Currently pregnant
- Prior needle or surgical biopsy of the lesion in question
For a listing of additional breast cancer clinical trials, please click here On that page, please click on "Search for Clinical Trials/Studies at Cedars-Sinai" and on the following page, type "Breast Cancer" into the search box.
For information concerning breast cancer clinical trials at Cedars-Sinai Medical Center, Please contact:
|Keri Ryback, RN, OCN|
|Samuel Oschin Comprehensive Cancer Institute|